Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (91-100 of 401) with videos related to

Pageof 41
Sort By:
Basic Research in Cardiology|April 2, 2026
Comparing anti-platelet and anti-thrombin therapies in the ischaemia-reperfusion injured coronary microcirculation of healthy and diabetic miceJoanne L Mitchell, Juma El-Awaisi, Dean Kavanagh, et al.
Thrombosis and Haemostasis|September 8, 2022
Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future DirectionsSem A O F Rikken, Robert F Storey, Felicita Andreotti, et al.
Journal of Cardiovascular Pharmacology|September 3, 2021
Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target EffectsMarco Valgimigli, Robert F Storey, Peter R Sinnaeve, et al.
Journal of the American College of Cardiology|July 7, 2019
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)Freek W A Verheugt, Jurriën M Ten Berg, Robert F Storey, et al.
Platelets|January 18, 2014
Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min periodWael Sumaya, Rajiv R Joshi, Heather M Judge, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2010
Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointimaShankar B Patil, Laura E Jackman, Sheila E Francis, et al.
Platelets|September 11, 2019
Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarctionBastiaan Zwart, Momina Yazdani, Kok Weng Ow, et al.
JACC. Cardiovascular Interventions|November 23, 2013
Response variability to P2Y12 receptor inhibitors: expectations and realityJolanta M Siller-Matula, Dietmar Trenk, Karsten Schrör, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|March 5, 2021
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial diseaseWilliam A E Parker, Diana A Gorog, Tobias Geisler, et al.
Journal of the American College of Cardiology|November 6, 2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialChristopher P Cannon, Steen Husted, Robert A Harrington, et al.
Pageof 41

Showing results (91-100 of 401) with videos related to

Sort By:
Pageof 41
Basic Research in Cardiology|April 2, 2026
Comparing anti-platelet and anti-thrombin therapies in the ischaemia-reperfusion injured coronary microcirculation of healthy and diabetic miceJoanne L Mitchell, Juma El-Awaisi, Dean Kavanagh, et al.
Thrombosis and Haemostasis|September 8, 2022
Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future DirectionsSem A O F Rikken, Robert F Storey, Felicita Andreotti, et al.
Journal of Cardiovascular Pharmacology|September 3, 2021
Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target EffectsMarco Valgimigli, Robert F Storey, Peter R Sinnaeve, et al.
Journal of the American College of Cardiology|July 7, 2019
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)Freek W A Verheugt, Jurriën M Ten Berg, Robert F Storey, et al.
Platelets|January 18, 2014
Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min periodWael Sumaya, Rajiv R Joshi, Heather M Judge, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2010
Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointimaShankar B Patil, Laura E Jackman, Sheila E Francis, et al.
Platelets|September 11, 2019
Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarctionBastiaan Zwart, Momina Yazdani, Kok Weng Ow, et al.
JACC. Cardiovascular Interventions|November 23, 2013
Response variability to P2Y12 receptor inhibitors: expectations and realityJolanta M Siller-Matula, Dietmar Trenk, Karsten Schrör, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|March 5, 2021
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial diseaseWilliam A E Parker, Diana A Gorog, Tobias Geisler, et al.
Journal of the American College of Cardiology|November 6, 2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialChristopher P Cannon, Steen Husted, Robert A Harrington, et al.
Pageof 41